References
- Dobay 0, et al. The first steps towards fluoroquinolone resistance in Hungarian pneumococci. J Chemother 2006; 18 (6): 624–7.
- Bast DJ et al. Fluoroquinolone resistance in clinical iso-lates of Streptococcus pneumoniae: contributions of type II topoisomerase mutations and efflux to levels of resistance. Antimicrob Agents Chemother, 2000; 44 (11): 3049–54.
- Munoz R, De La Campa AG. ParC subunit of DNA topoisomerase IV of Streptococcus pneumoniae is a primary target of fluoroquinolones and cooperates with DNA gyrase A subunit in forming resistance phenotype. Antimicrob Agents Chemother, 1996; 40 (10): 2252–7.
- Kays MB et al. Selection of a gyrA mutation and treat-ment failure with gatifloxacin in a patient with Streptococcus pneumoniae with a preexisting parC mutation. Pharma-cotherapy, 2007; 27 (2): 221–6.
- McGee L, et al. Nomenclature of major antimicrobial-resistant clones of Streptococcus pneumoniae defined by the pneumococcal molecular epidemiology network. J Clin Microbiol, 2001; 39 (7): 2565–71.
- Ho PL et al. Fluoroquinolone resistance among Streptococcus pneumoniae in Hong Kong linked to the Spanish 23F clone. Emerg Infect Dis 2001; 7 (5): 906–8.
- McGee L, Goldsmith CE, Klugman KP. Fluoroquinolone resistance among clinical isolates of Streptococcus pneumoni-ae belonging to international multiresistant clones. J Antimicrob Chemother, 2002; 49 (1): 173–6.
- Alou L et al. Streptococcus pneumoniae isolates with reduced susceptibility to ciprofloxacin in Spain: clonal diversity and appearance of ciprofloxacin-resistant epidemic clones. Antimicrob Agents Chemother, 2001; 45 (10): 2955–7.
- Pletz MW et al. Prevalence of first-step mutants among levofloxacin-susceptible invasive isolates of Streptococcus pneumoniae in the United States. Antimicrob Agents Chemother, 2006; 50 (4): 1561–3.
- de la Campa AG et al. Fluoroquinolone resistance in penicillin-resistant Streptococcus pneumoniae clones, Spain. Emerg Infect Dis, 2004; 10 (10): 1751–9.